GE Healthcare Technologies Inc

Latest Results (28.08.2026):

GE Healthcare Technologies Inc — second quarter 2026: The company reported solid top-line growth with revenues of $5.3 billion (up 5.7%) and organic revenue growth of 3.5%, record organic orders growth of 11.1%, and a $23.9 billion backlog. GAAP net income attributable to the company was $561 million (net income margin 10.6%) and diluted EPS was $1.24. Adjusted EBIT was $750 million (14.2% margin) and adjusted EPS was $1.13. Cash from operations was $168 million and free cash flow was $68 million. Management reaffirmed full‑year 2026 guidance.

Revenue

Total revenues were $5.295 billion, up 5.7% year‑over‑year, driven by strength in Advanced Imaging Solutions and Pharmaceutical Diagnostics; organic revenue rose 3.5%.

Profitability & EPS

Net income attributable to GE Healthcare Technologies Inc was $561 million (net margin 10.6%, +90 bps year‑over‑year). Diluted EPS was $1.24 (+$0.18). Adjusted EBIT was $750 million with a 14.2% adjusted EBIT margin (down 40 bps vs. prior year). Adjusted EPS was $1.13.

Orders, Book‑to‑Bill & Backlog

Record organic orders growth of 11.1%, book‑to‑bill of 1.15x, and backlog of $23.9 billion — signaling continued demand momentum.

Segment Performance

Advanced Imaging Solutions: revenues +7.9% (organic +5.0%) and EBIT margin 13.9% (+90 bps). Pharmaceutical Diagnostics: revenues +15.6% (organic +14.6%) and margin 29.6% (+30 bps). Patient Care Solutions: revenues down 13.3% (organic -13.5%) and EBIT margin -3.8% (down ~1,150 bps), reflecting ongoing challenges in PCS.

Tariff Refunds & Adjustments

Quarterly results were helped by IEEPA tariff refunds; the company noted a material benefit to net income and specified tariff‑related amounts that were included/excluded from certain adjusted measures (company disclosed $129 million benefit to net income and related adjustments around $106 million for adjusted results tied to 2025 items).

Cash, Capital Deployment & Balance Sheet

Cash and equivalents ~$2.1 billion, total debt ~$10.1 billion. Cash from operations $168 million (up $74M yr/yr) and free cash flow $68 million. The company repurchased 3.3 million shares for ~$200 million (about $500 million remaining authorization) and declared a quarterly dividend of $0.035 per share.

Guidance

GE Healthcare Technologies Inc reaffirmed full‑year 2026 outlook: organic revenue growth 3.0–4.0%, adjusted EBIT margin 15.4–15.7%, adjusted EPS $4.80–$5.00, adjusted ETR ~20–21%, and free cash flow of approximately $1.6 billion. Guidance excludes 2025 tariff refund benefits from adjusted EBIT assumptions.

Commercial & Innovation Updates

Company highlighted partnerships and product progress including theranostics collaborations (Mayo Clinic, University Hospital Essen), cloud-enabled enterprise imaging, and FDA 510(k) activity for AI-enabled radiation therapy and 4D PET imaging submissions.